• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[大隐静脉移植血管病变:病因、预防及当代治疗策略]

[Saphenous vein graft disease: causes, prevention, and contemporary treatment strategies].

作者信息

Gökay Seher, Ciçek Davran

机构信息

Department of Cardiology, Başkent University Alanya Practice and Research Hospital, Antalya, Turkey.

出版信息

Turk Kardiyol Dern Ars. 2012 Dec;40(8):736-43. doi: 10.5543/tkda.2012.26790.

DOI:10.5543/tkda.2012.26790
PMID:23518892
Abstract

Coronary bypass graft surgery provides symptomatic relief and a long life expectancy for most patients with coronary artery disease who have suitable vessels. Although arterial conduits are becoming more popular, saphenous vein grafts (SVG) are still frequently used in coronary artery bypass surgery since they are readily available, especially in emergency situations. However, SVG tend to degenerate over time, as nearly half of them develop significant stenosis and nearly 40% of them become completely occluded within a decade. Treatment options for SVG failure include redo-surgery, percutaneous intervention, and/or medical therapy. However, challenges in maintaining graft patency (as a predictor of long-term survival) and interventional complications (e.g., distal embolization, ''no-reflow,'' and higher rates of periprocedural myocardial infarction) are still ongoing problems for cardiologists and cardiovascular surgeons. This review discusses the possible causes of graft failure and the contemporary approaches for improving outcomes in patients undergoing coronary artery bypass graft surgery with at least one SVG.

摘要

冠状动脉旁路移植术能为大多数有合适血管的冠心病患者缓解症状并延长预期寿命。尽管动脉移植物越来越受欢迎,但大隐静脉移植物(SVG)在冠状动脉旁路手术中仍经常使用,因为它们容易获取,尤其是在紧急情况下。然而,SVG往往会随着时间推移而退化,近一半的SVG会出现明显狭窄,近40%的SVG会在十年内完全闭塞。SVG失败的治疗选择包括再次手术、经皮介入治疗和/或药物治疗。然而,维持移植物通畅(作为长期生存的预测指标)和介入并发症(如远端栓塞、“无复流”以及围手术期心肌梗死发生率较高)仍是心脏病专家和心血管外科医生面临的持续问题。本综述讨论了移植物失败的可能原因以及改善至少使用一个SVG进行冠状动脉旁路移植术患者预后的当代方法。

相似文献

1
[Saphenous vein graft disease: causes, prevention, and contemporary treatment strategies].[大隐静脉移植血管病变:病因、预防及当代治疗策略]
Turk Kardiyol Dern Ars. 2012 Dec;40(8):736-43. doi: 10.5543/tkda.2012.26790.
2
Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions.冠状动脉旁路移植术后大隐静脉桥失败:病理生理学、处理方法和未来方向。
Ann Surg. 2013 May;257(5):824-33. doi: 10.1097/SLA.0b013e318288c38d.
3
Predictors of periprocedural complications in patients undergoing percutaneous coronary interventions within coronary artery bypass grafts.经皮冠状动脉介入治疗在冠状动脉旁路移植术中围手术期并发症的预测因素。
Cardiol J. 2019;26(6):633-644. doi: 10.5603/CJ.a2018.0044. Epub 2018 Apr 19.
4
Current percutaneous treatment strategies for saphenous vein graft disease.当前治疗隐静脉移植物病变的经皮治疗策略。
Catheter Cardiovasc Interv. 2013 Sep 1;82(3):406-13. doi: 10.1002/ccd.24554. Epub 2013 Jun 5.
5
Saphenous vein graft intervention.隐静脉移植介入治疗。
JACC Cardiovasc Interv. 2011 Aug;4(8):831-43. doi: 10.1016/j.jcin.2011.05.014.
6
Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft.乳内动脉桥对隐静脉移植血管经皮介入术后长期预后的影响
Circulation. 2006 Jul 4;114(1 Suppl):I396-401. doi: 10.1161/CIRCULATIONAHA.105.000349.
7
Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial.支架置入术后大隐静脉移植物失败的临床表现及血管造影特征:来自SOS(大隐静脉移植物支架置入)试验的见解
JACC Cardiovasc Interv. 2009 Sep;2(9):855-60. doi: 10.1016/j.jcin.2009.06.014.
8
Radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: a randomized trial.冠状动脉旁路移植术中桡动脉移植物与隐静脉移植物的比较:一项随机试验。
JAMA. 2011 Jan 12;305(2):167-74. doi: 10.1001/jama.2010.1976.
9
Tirofiban administration and percutaneous coronary intervention with stenting of saphenous vein graft thrombosis.替罗非班给药和经皮冠状动脉介入术治疗隐静脉桥血栓形成。
J Cardiovasc Med (Hagerstown). 2009 Nov;10(11):875-8. doi: 10.2459/JCM.0b013e32832e669a.
10
Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters.大隐静脉移植血管造影标记物对临床事件和血管造影参数的影响。
Ann Thorac Surg. 2008 Feb;85(2):520-4. doi: 10.1016/j.athoracsur.2007.10.061.

引用本文的文献

1
The Role of Advanced Glycation End Products in Saphenous Vein Graft Failure.晚期糖基化终末产物在大隐静脉移植失败中的作用。
Med Princ Pract. 2025;34(1):87-95. doi: 10.1159/000541879. Epub 2024 Oct 9.
2
Prognostic Value of Systemic Immune-Inflammation Index in Predicting Premature Saphenous Vein Graft Disease in Patients With Coronary Artery Bypass Grafting.全身免疫炎症指数在预测冠状动脉旁路移植术患者大隐静脉移植血管早期病变中的预后价值
Cureus. 2023 Aug 2;15(8):e42833. doi: 10.7759/cureus.42833. eCollection 2023 Aug.
3
Role of Urotensin-II in Saphenous Vein Graft Disease.
尾加压素-II 在大隐静脉移植病变中的作用。
Braz J Cardiovasc Surg. 2020 Oct 1;35(5):675-682. doi: 10.21470/1678-9741-2019-0470.